Mylan surges as its generic of Teva's Copaxone gets FDA nod


Shares of Mylan NV jumped about 17 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's copycat version of Teva Pharmaceutical Industries Ltd's blockbuster multiple sclerosis drug. Mylan's shares were trading at $38 and was top gainer among S&P 500 components trading before the opening bell.



from Biotech News